tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Feb 12;9(2):147.
doi: 10.3390/vaccines9020147.
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Emily Bettini[SUP] 1 [/SUP], Michela Locci[SUP] 1 [/SUP]
Affiliations
Abstract
To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive immunity, including B and T cell responses. While B cell responses are key, as they can mediate antibody-dependent protection, T cells can modulate B cell activity and directly contribute to the elimination of pathogen-infected cells. In the unprecedented race to develop an effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the respiratory disease coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) vaccines have emerged as front runners thanks to their capacity for rapid development and ability to drive potent adaptive immune responses. In this review article, we provide an overview of the results from pre-clinical studies in animal models as well as clinical studies in humans that assessed the efficacy of SARS-CoV-2 mRNA vaccines, with a primary focus on adaptive immune responses post vaccination.
Keywords: SARS-CoV-2; T follicular helper cells; Th1 cells; adaptive immunity; antibodies; coronavirus; germinal centers; long-lived plasma cells; mRNA vaccines; memory B cells.
. 2021 Feb 12;9(2):147.
doi: 10.3390/vaccines9020147.
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Emily Bettini[SUP] 1 [/SUP], Michela Locci[SUP] 1 [/SUP]
Affiliations
- PMID: 33673048
- DOI: 10.3390/vaccines9020147
Abstract
To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive immunity, including B and T cell responses. While B cell responses are key, as they can mediate antibody-dependent protection, T cells can modulate B cell activity and directly contribute to the elimination of pathogen-infected cells. In the unprecedented race to develop an effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the respiratory disease coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) vaccines have emerged as front runners thanks to their capacity for rapid development and ability to drive potent adaptive immune responses. In this review article, we provide an overview of the results from pre-clinical studies in animal models as well as clinical studies in humans that assessed the efficacy of SARS-CoV-2 mRNA vaccines, with a primary focus on adaptive immune responses post vaccination.
Keywords: SARS-CoV-2; T follicular helper cells; Th1 cells; adaptive immunity; antibodies; coronavirus; germinal centers; long-lived plasma cells; mRNA vaccines; memory B cells.